MarketBeat
22 Nov 2026, 06:12 UTC · 9h ago
Nektar Therapeutics Maps Key REZPEG Data Milestones for 2027 and 2028
Impact · against what's priced in
Nektar's provided roadmap establishes a long-dated binary catalyst window with a primary readout in summer 2028, shifting the stock's driver to speculative sentiment and intermediate durability data. While the expansion into alopecia areata adds pipeline value, it tightens the cash runway to just one quarter past the critical Phase 3 results, increasing the likelihood of near-term dilution.
- NKTR+0.30
No priced-in read yet
- In context
The stock gains a specific timeline for its REZPEG program, including a potential valuation-boosting durability readout in Q1 2027 and a Phase 3 induction result in summer 2028. However, the cost of a new 850-patient alopecia study and existing burn leaves the company financed only through Q3 2028, creating a tight window between the data readout and cash exhaustion.

- NKTR
- alopecia areata
- atopic dermatitis
- autoimmune disease
- biopharma
- clinical trials
- drug pipeline
- phase 3
- rd spending
- vitiligo
Search tags




